Send to

Choose Destination
Blood Adv. 2018 Feb 27;2(4):454-461. doi: 10.1182/bloodadvances.2017010660.

Eltrombopag for use in children with immune thrombocytopenia.

Author information

Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX.
Texas Children's Cancer and Hematology Centers, Houston, TX.
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and.
Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA.


Eltrombopag is currently the only US Food and Drug Administration-approved thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) in children. This oral, once-per-day therapy has shown favorable efficacy and adverse effect profiles in children. Two multicenter, double-blind, placebo controlled clinical trials (PETIT [Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)] and PETIT2 [Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body]) demonstrated efficacy in raising platelet counts, reducing bleeding, and reducing the need for concomitant ITP therapies with relatively few adverse effects. The most commonly reported drug-related adverse effects include headache, nausea, and hepatobiliary laboratory abnormalities. Long-term safety data in children are limited, and studies in adults have not revealed a clinically significant increased incidence of thrombosis, marrow fibrosis, or cataract formation. Eltrombopag has also been approved for treating refractory severe aplastic anemia (AA) and has potential for expanded use in ITP and severe AA as well as in other conditions associated with thrombocytopenia.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center